JG
NXTM

Joel Greenblatt’s NxStage Medical Inc. NXTM Stock Holding History

Joel Greenblatt’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-18,781
Closed -$407K – 1107
2016
Q2 		$407K Buy
+18,781
New +$335K ﹤0.01% 761

Other funds holding NXTM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Joel Greenblatt's NXTM Position: Q3 2016 in Review

Joel Greenblatt sold out of NxStage Medical Inc. (NXTM) in Q3 2016, closing a stake of 18,781 shares — an estimated $407K sold.

Joel Greenblatt first reported a position in NXTM in Q2 2016 and held it in 1 quarter. The position peaked at $407K in Q2 2016. 156 funds tracked by Wall St. Rank hold NXTM as of Q3 2016.

  • Joel Greenblatt reported no remaining NxStage Medical Inc. position as of Q3 2016 after selling out during the quarter.
  • Joel Greenblatt sold 18,781 NxStage Medical Inc. shares in Q3 2016, an estimated $407K.
  • Joel Greenblatt first reported a position in NxStage Medical Inc. in Q2 2016 and held it in 1 quarter.
  • Joel Greenblatt's NxStage Medical Inc. position peaked at $407K in Q2 2016.
  • 156 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q3 2016.

Based on Gotham Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.